Table 1.

Studies investigating therapeutic effects of dantrolene in treating AD through different administration routes.

Model Used	Administration Route	Dantrolene Brain Concentration	Outcome	References
3xTg-AD	ICV and SQ	ICV: 200–10,090 ng/g SQ: N/A	Decreased memory loss, Improved memory learning, and reduced Aβ burden and plaque formation in the hippocampus.	[25]
Tg2576	SQ	N/A	Decreased Aβ burden, senile plaque formation, and learning deficits.	[24]
APPPS1	Oral	N/A	Increased amyloid load, loss of hippocampal excitatory synaptic markers, and neuronal atrophy.	[26]
5XFAD	IN	SQ at 20 min: 110–150 ng/g IN at 20 min: 110–250 ng/g SQ at 60 min: 90–110 ng/g IN at 60 min: 150–260 ng/g	Ameliorated memory loss, more effective than SQ, and did not change Aβ burden in comparison to control.	[32]